ASH 2019 | Venetoclax with mini-hyper-CVD for ALL
Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results from the multicenter phase I study combining venetoclax with mini-hyperfractionated cyclophosphamide, vincristine and dexamethasone (mini-hyper-CVD) in older adults with untreated or relapsed/refractory acute lymphoblastic leukemia (ALL). Although the complete remission and MRD rates were exceptionally high, longer follow-up is needed. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
Get great new content delivered to your inboxSign up